TY - JOUR
T1 - The Cooperative Human Tissue Network of the National Cancer Institute
T2 - Supporting Cancer Research for 35 Years
AU - McCall, Shannon J.
AU - Lubensky, Irina A.
AU - Moskaluk, Christopher A.
AU - Parwani, Anil
AU - Radin, Kiley
AU - Ramirez, Nilsa C.
AU - Von Menchhofen, Zachery
AU - Washington, Mary K.
AU - LiVolsi, Virginia A.
N1 - Publisher Copyright:
© 2023 American Association for Cancer Research.
PY - 2023/10/1
Y1 - 2023/10/1
N2 - The Cooperative Human Tissue Network was created by the NCI in 1987 to support a coordinated national effort to collect and distribute high quality, pathologist-validated human tissues for cancer research. Since then, the network has expanded to provide different types of tissue samples, blood and body fluid samples, immunohistologic and molecular sample preparations, tissue microarrays, and clinical datasets inclusive of biomarkers and molecular testing. From inception through the end of 2021, the network has distributed 1,375,041 biospecimens. It served 889 active investigators in 2021. The network has also taken steps to begin to optimize the representation of diverse communities among the distributed biospecimens. In this article, the authors review the 35-year history of this network, describe changes to the program over the last 15 years, and provide operational and scientific highlights from each of the divisions. Readers will learn how to engage with the network and about the continued evolution of the program for the future.
AB - The Cooperative Human Tissue Network was created by the NCI in 1987 to support a coordinated national effort to collect and distribute high quality, pathologist-validated human tissues for cancer research. Since then, the network has expanded to provide different types of tissue samples, blood and body fluid samples, immunohistologic and molecular sample preparations, tissue microarrays, and clinical datasets inclusive of biomarkers and molecular testing. From inception through the end of 2021, the network has distributed 1,375,041 biospecimens. It served 889 active investigators in 2021. The network has also taken steps to begin to optimize the representation of diverse communities among the distributed biospecimens. In this article, the authors review the 35-year history of this network, describe changes to the program over the last 15 years, and provide operational and scientific highlights from each of the divisions. Readers will learn how to engage with the network and about the continued evolution of the program for the future.
UR - http://www.scopus.com/inward/record.url?scp=85176496572&partnerID=8YFLogxK
U2 - 10.1158/1535-7163.MCT-22-0714
DO - 10.1158/1535-7163.MCT-22-0714
M3 - Article
C2 - 37523711
AN - SCOPUS:85176496572
SN - 1535-7163
VL - 22
SP - 1182
EP - 1190
JO - Molecular Cancer Therapeutics
JF - Molecular Cancer Therapeutics
IS - 10
ER -